

Information on ASCO (from homepage)

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology.

ASCO is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

ASCO was founded in 1964 by a small group of physician members of the American Association of Cancer Research (AACR) who recognized the need for the creation of a separate society dedicated to issues unique to clinical oncology. Read on to explore ASCO's roots through a series of in-depth articles and experience the history of the Society through multimedia vignettes from the people who believed in ASCO from the beginning.

Program from ASCO-GU congress 2010

7:00 AM - 6:00 PM

Exhibit Hall Open

7:00 AM - 8:00 AM

Continental Breakfast Provided

8:00 AM - 8:10 AM

Welcome

8:10 AM - 9:45 AM

General Session I: Prostate Cancer - Screening and Prevention

Co- Leonard G. Gomella, MD, FACS - Thomas Jefferson University

Chairs: Ralph W. deVere White, MB, BCh, BAO - UC Davis Cancer Center

The Case For Screening

Peter R. Carroll, MD, MPH - University of California, San Francisco

The Case Against Screening

Peter Boyle, PhD, DSc - International Prevention Research Institute

Balancing the Risks and Benefits of Prevention

Eric A. Klein, MD - Cleveland Clinic

Integration of Screening and Prevention in the 21st Century

Otis W. Brawley, MD - American Cancer Society

Abstract #1: Urine measurement of TMPRSS2:ERG for the early detection of significant prostate cancer

John T. Wei, MD, MS - University of Michigan

(First author: Sheila M. J. Aubin, PhD - Gen-Probe Incorporated)

Abstract #2: Improved prediction of prostate biopsy outcome by incorporating TMPRSS2:ERG and other risk factors into a logistic regression model

James B. Amberson, MD - Dianon Systems, Inc.

(First author: John R. Day, PhD - Gen-Probe Incorporated)

Question and Answer Session

9:45 AM - 10:15 AM

Break

10:15 AM - 11:45 AM

General Session II: Prostate Cancer - Integrated Care for High-risk Disease

Co-Chairs: Robert S. DiPaola, MD - The Cancer Institute of New Jersey

Mark A. Ritter, MD, PhD - University of Wisconsin Clinical Cancer Center

All High-risk Disease is Not the Same

Joel B. Nelson, MD - University of Pittsburgh School of Medicine

Usefulness of Imaging in High-risk Prostate Cancer

Mukesh G. Harisinghani, MD - Dana-Farber/Harvard Cancer Center

The Case for Surgery in High-risk Disease

Judd W. Moul, MD - Duke University

The Case for Radiotherapy in High-risk Disease

Mack Roach, III, MD. FACR - University of California, San Francisco

Androgen Suppression and Cardiovascular Mortality

Matthew R. Smith, MD, PhD - Massachusetts General Hospital

Question and Answer Session

11:45 AM - 1:15 PM

General Poster Session A (Boxed Lunch Provided)

11:50 AM - 1:05 PM

Translational Science Sessions

Ticket Required/Boxed Lunch Provided

Prostate Cancer

Mechanisms by which the Androgen Receptor Mediates Prostate Cancer

Donald J. Tindall, PhD - Mayo Clinic

Synthesis of Androgens by the Prostate Tumor
Edward P. Gelmann, MD - Columbia University

Renal Cancer

HIF1 Alpha/HIF2 Alpha Distinctions in Kidney Cancer Biology
Katherine L. Nathanson, MD, FACMG, FACP - University of Pennsylvania

Role of PI3-Kinase Pathway and Targeting
Daniel C. Cho, MD, MS, MSc - Beth Israel Deaconess Medical Center

Biology and Management of Acquired Resistance of the VEGF Pathway
Michael B. Atkins, MD - Beth Israel Deaconess Medical Center

1:15 PM - 2:45 PM

Oral Abstract Session A: Prostate Cancer

Co-Chairs: Scott G. Williams, MD - Peter MacCallum Cancer Centre (Melbourne, Australia)

Alan Pollack, MD, PhD - University of Miami - Miller School of Medicine

[Abstract #5](#): Validation of the PCA3 molecular urine test for predicting repeat prostate biopsy outcome in the placebo arm of the dutasteride REDUCE trial.

Leonard S. Marks, MD - Geffen School of Medicine at UCLA (First author: Jack Groskopf, PhD - Gen-Probe, Incorporated)

[Abstract #6](#): Effect of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: Initial results of RTOG 94-08.

David G. McGowan, MB.ChB, FRCPC - Cross Cancer Institute

[Abstract #7](#): A phase III trial of docetaxel-estramustine in high risk localized prostate cancer (GETUG 12 trial): Design, tolerance, response, and quality of life (QOL).

Karim Fizazi, MD, PhD - Institut Gustave Roussy

[Abstract #8](#): Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration resistant prostate cancer (CRPC).

Philip Kantoff, MD - Dana-Farber Cancer Institute

[Abstract #9](#): Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

A. Oliver Sartor, MD - Tulane University

[Abstract #10](#): Twenty-four months after prostate cancer treatment: Partner's appraisal of the cancer experience and partner quality of life.

Janet K. Harden, PhD - Wayne State University College of Nursing

Abstract #11: Comparison of health-related quality of life 5 years after SPIRIT (Surgical Prostatectomy (RP) vs. interstitial radiation (BT) intervention trial ACOSOG Z0070).

Juanita M. Crook, MD, FRCPC - British Columbia Cancer Agency

Abstract #12: Use of biopsy Ki-67 to predict systemic progression and cancer-specific death following radical prostatectomy.

Matthew Kevin Tollefson, M.D - Mayo Clinic

Abstract #13: Single nucleotide polymorphisms (SNPs) in the matrix metalloproteinase (MMP) gene family, gastroesophageal reflux disease (GERD), and risk of esophageal adenocarcinoma (EAC)

Andrew Loblaw, MSc, MD, FRCPC – University of Toronto

(First author: Laurence Klotz, MD - Sunnybrook Health Sciences Centre)

2:45 PM - 3:15 PM

Break

3:15 PM - 4:45 PM

General Session III: Prostate Cancer - Future Pathways: What is on the Way?

Co- Maha H. Hussain, MD - University of Michigan

Chairs: Howard I. Scher, MD - Memorial Sloan-Kettering Cancer Center

Abstract #3: Effect of luteinizing hormone on the steroid biosynthesis pathway in prostate cancer.

Jacek K. Pinski, MD, PhD - University of Southern California Norris Comprehensive Cancer Center

Abstract #4: Bone scan flare in patients (pts) receiving abiraterone acetate (AA) for metastatic androgen deprivation-resistant prostate cancer (mADRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Shreya Shah, MD - University of California, San Francisco

The Androgen Receptor and Prostate Cancer: State of the ART

Donald J. Tindall, PhD - Mayo Clinic

AR Pathways

Charles J. Ryan, MD - University of California, San Francisco

Non-AR Targeted Pathways

Wm. Kevin Kelly, DO - Yale Cancer Center

Immunologic Therapies

Charles G. Drake, MD, PhD - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Question and Answer Session

4:45 PM - 6:00 PM

Reception and General Poster Session B: Prostate Cancer (Wine and Cheese Provided)

4:55 PM - 6:00 PM

Fellows Poster Walk: Prostate (*Ticket Required - Attendance Limited to Fellows, Residents, and Junior Faculty*)

Walk Leaders: Alan Pollack, MD, PhD - University of Miami - Miller School of Medicine
Howard I. Scher, MD - Memorial Sloan-Kettering Cancer Center

Saturday, March 6, 2010

7:00 AM - 6:45 PM

Exhibit Hall Open

7:00 AM - 8:00 AM

Best of Journals Session: Prostate Cancer

Ticket Required/Continental Breakfast Provided

Co-Chairs: W. Robert Lee, MD, MS - Duke University Medical Center
Joel B. Nelson, MD - University of Pittsburgh School of Medicine
Matthew R. Smith, MD, PhD - Massachusetts General Hospital

7:00 AM - 8:00 AM

Continental Breakfast Provided

8:10 AM - 8:15 AM

Welcome

8:15 AM - 10:00 AM

General Session IV: Cancers of the Urothelium

Co-Chairs: Harry W. Herr, FACS - Memorial Sloan-Kettering Cancer Center
Eila C. Skinner, MD - University of Southern California

The Current Role of CT Urography and MR Urography in the Evaluation of the Upper Urinary Tract

Stuart G. Silverman, MD - Dana-Farber/Harvard Cancer Center

Optimizing Responses to Bacillus Calmette Guérin for Non-muscle Invasive Bladder Cancer: Role of Inflammation and Cytokine Biomarkers

Ashish M. Kamat, MD, FACS - M. D. Anderson Cancer Center

What is the Surgical Standard for Pelvic Lymphadenectomy and Radical Cystectomy?

Seth P. Lerner, MD - Baylor College of Medicine

Optimizing Systemic Therapy for Advanced Urothelial Cancer

Joaquim Bellmunt, MD - University Hospital del Mar (Barcelona, Spain)

Abstract #273: 15-year outcomes of selective bladder preservation for invasive bladder cancer: The Massachusetts General Hospital experience.

Jason Alexander Efstathiou, MD, DPhil - Massachusetts General Hospital

Question and Answer Session

10:00 AM - 10:30 AM

Break

10:30 AM - 11:45 AM

General Session V: Tumor Board Discussion on Rare Tumors of the GU Tract

Co- Dean F. Bajorin, MD - Memorial Sloan-Kettering Cancer Center

Chairs: Deborah A. Kuban, MD - M. D. Anderson Cancer Center

Panel: **Radiological Perspective:** Stuart G. Silverman, MD - Dana-Farber/Harvard Cancer Center

Urological Oncology Perspective: Cheryl T. Lee, MD - University of Michigan

Medical Oncology Perspective: George J. Bosl, MD - Memorial Sloan-Kettering Cancer Center

Pathology Perspective: David J. Grignon, MD, FRCPC - Indiana University

Radiation Oncology Perspective: Anthony L. Zietman, MD - Massachusetts General Hospital

Topics: **Prostate Case**
Bladder Case
Kidney/Lesion in Kidney Case

11:45 AM - 12:30 PM

Keynote Lecture - How the Epigenome Changes in Cancer

Introduction: Howard M. Sandler, MD - Cedars-Sinai Medical Center

How the Epigenome Changes in Cancer

Peter A. Jones, PhD, DSc - USC/Norris Comprehensive Cancer Center

12:30 PM - 2:00 PM

General Poster Session C: Prostate Cancer (*Boxed Lunch Provided*)

12:40 PM - 1:45 PM

Fellows, Residents, and Junior Faculty Networking Luncheon

Ticket Required

Co-Chairs: Ralph W. deVere White, MB, BCh, BAO - UC Davis Cancer Center
Maha H. Hussain, MD - University of Michigan

2:00 PM - 3:30 PM

Oral Abstract Session B: Prostate, Testis, Bladder, and Other GU Neoplasms

Co-Chairs: Christopher Cheng, MBBS, FRCS, M Med (Surg), FAMS - Singapore General Hospital
Naomi Haas, MD - University of Pennsylvania Abramson Cancer Center

[Abstract #14:](#) Fifteen-year biochemical relapse-free survival and overall survival following 125I prostate brachytherapy in clinically localized prostate cancer: Seattle experience.

John E. Sylvester, MD - Seattle Prostate Cancer Center

[Abstract #15:](#) Cell cycle progression genes predict recurrence after radical prostatectomy.

Gregory Peter Swanson, MD - University of Texas Health Science Center at San Antonio

[Abstract #16:](#) Effect of TMPRSS2/ERG fusion gene expression on radio- and chemo-responsiveness in prostate cancer cell lines.

Todd A. Swanson, MD, PhD - William Beaumont Hospital

[Abstract #17:](#) The relationship between androgen receptor and pro-angiogenic gene expression levels in prostate cancer and their prognostic value.

Tanya B. Dorff, MD - University of Southern California Norris Comprehensive Cancer Center

[Abstract #18:](#) Time trends in the utilization of higher-cost treatments for prostate cancer, 2002-2007.

Paul Linh Nguyen, MD - Dana-Farber Cancer Institute/Brigham and Women's Hospital

[Abstract #274:](#) Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?

Edward M. Messing, MD - University of Rochester Medical Center

[Abstract #275:](#) Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.

Jose A. Karam, MD - University of Texas M. D. Anderson Cancer Center

[Abstract #248:](#) Extensive inguinal lymphadenectomy in high-risk penile cancer improves overall five-year survival: A SEER study.

Viraj A Master, MD, PhD - Emory University

[Abstract #256:](#) 2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: a retrospective validation of the SEMPET trial.

Mark Bachner, MD - ACR-ITR Vienna

3:30 PM - 4:00 PM

Break

4:00 PM - 5:30 PM

General Session VI: Renal Cancer - Localized Kidney Tumors: Pathology and Diagnosis

Co- David Y. Chen, MD, FACS - Fox Chase Cancer Center

Chairs: Ronald J. Zagoria, MD, FACR - Wake Forest University Health Sciences

What Does the Practicing Oncologist Need to Know About Kidney Pathology?

Victor E. Reuter, MD - Memorial Sloan-Kettering Cancer Center

Molecular Imaging for Phenotypic Characterization of Urologic Cancers: Implication for Management and Targeted Therapy (G250 PET)

Chaitanya R. Divgi, MD - University of Pennsylvania

Rationale and Potential Pitfalls of Active Surveillance for Small Kidney Tumors

Michael A.S. Jewett, MD, FRCSC, FACS - Princess Margaret Hospital/University of Toronto

Abstract #310: Active surveillance of an incidental renal mass in the setting of an active or recently treated non-renal malignancy.

Frances M Alba, MD - University of Texas Health Science Center at Houston

Role of Thermal Ablation in the Management of Small Renal Masses

The Case Against Thermal Ablation - David Y. Chen, MD, FACS - Fox Chase Cancer Center

The Case For Thermal Ablation - Debra A. Gervais, MD - Massachusetts General Hospital

Question and Answer Session

5:30 PM - 6:45 PM

Reception and General Poster Session D: Testis, Bladder, Renal and Other GU Neoplasms (Wine and Cheese Provided)

5:40 PM - 6:45 PM

Fellows Poster Walk: Renal (*Ticket Required - Attendance Limited to Fellows, Residents, and Junior Faculty*)

Walk Leaders: Michael A. S. Jewett, MD, FRCSC, FACS - Princess Margaret Hospital/University of Toronto

Elisabeth I. Heath, MD - Karmanos Cancer Center

Sunday, March 7, 2010

7:00 AM - 8:00 AM

Best of Journals Session: Renal Cancer

Ticket Required/Continental Breakfast Provided

Co- J. Louis Hinshaw, MD - University of Wisconsin School of Medicine and Public
Chairs: Health
Gary R. Hudes, MD - Fox Chase Cancer Center
Christopher G. Wood, MD, FACS - M.D. Anderson Cancer Center

7:00 AM - 8:00 AM

Continental Breakfast Provided

7:00 AM - 8:15 AM

**General Poster Session E: Testis, Bladder, Renal and Other GU Neoplasms
(Continental Breakfast Provided)**

8:10 AM - 8:15 AM

Welcome

8:15 AM - 9:45 AM

General Session VII: Renal Cancer - Surgical Management of Kidney Tumors

Co- Paul Russo, MD, FACS - Memorial Sloan-Kettering Cancer Center
Chairs: Toni K. Choueiri, MD - Dana-Farber/Harvard Cancer Center

**What All Oncologists Need to Know About Estimated Glomerular Filtration
Rate**

Lesley A. Stevens, MD, MS, FRCPC - Tufts University School of Medicine

The Oncologic and Medical Rationale for Partial Nephrectomy

Paul Russo, MD, FACS - Memorial Sloan-Kettering Cancer Center

**Management of Regionally Advanced Renal Cell (IVC and Lymph Node
Management)**

Michael L. Blute, MD - Mayo Clinic

**Adjuvant/Neo-adjuvant Strategies Integrating Surgery and Targeted
Therapies**

Hein van Poppel, MD, PhD - University Hospitals Leuven

**[Abstract #311](#): The impact of cytoreductive nephrectomy in patients with
metastatic renal cell carcinoma (mRCC) treated with vascular endothelial
growth factor (VEGF)-targeted therapy**

Toni K. Choueiri, MD, MS - Dana-Farber Cancer Institute/Harvard Medical
School

Question and Answer Session

9:45 AM - 10:00 AM

Break

10:00 AM - 11:30 AM

Oral Abstract Session C: Renal Cancer

Co-Chairs: Robert J. Motzer, MD - Memorial Sloan-Kettering Cancer Center

Paul Russo, MD, FACS - Memorial Sloan-Kettering Cancer Center

[Abstract #313](#): Pathological upstaging does not affect survival in patients with pT2/T3 renal tumors treated by either partial nephrectomy (PN) or radical nephrectomy (RN)

Christopher J. Weight, MD - Cleveland Clinic

[Abstract #314](#): Race determines histological subtypes and stage of RCC: An analysis of the SEER database.

Paul H. Chung, MD - Urologic Oncology Branch, National Cancer Institute

[Abstract #315](#): Every minute counts when you clamp the renal hilum during partial nephrectomy .

Robert Houston Thompson, MD - Mayo Clinic

[Abstract #316](#): Radiofrequency ablation (RFA) of renal tumors: Clinical, radiographic, and pathologic results from a tertiary cancer center.

Jose A. Karam, MD - University of Texas M. D. Anderson Cancer Center

[Abstract #317](#): Effect of complete resection for multiple metastases of renal cell carcinoma on survival.

Angela L. Alt, MD - Department of Urology, Mayo Clinic

[Abstract #318](#): Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?

Edwin Jason Abel, MD - M. D. Anderson Cancer Center

[Abstract #319](#): Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma.

Brian I. Rini, MD - Cleveland Clinic

[Abstract #320](#): Use of MDM2 to link survival and invasiveness in renal cell carcinoma and as a novel drug target for therapy.

Mark T. Boyd, B.Sc., Ph.D. - University of Liverpool

[Abstract #321](#): The high-dose aldesleukin (HD IL-2) "Select" trial in patients with metastatic renal cell carcinoma (mRCC): Preliminary assessment of clinical benefit.

David F. McDermott, MD - Beth Israel Deaconess Medical Center

11:30 AM - 12:30 PM

General Poster Session E: Testis, Bladder, Renal and Other GU Neoplasms (Boxed Lunch Provided)

12:30 PM - 2:00 PM

General Session VIII: Renal Cancer - Metastatic RCC

Co- Robert J. Motzer, MD - Memorial Sloan-Kettering Cancer Center

Chairs: Christopher G. Wood, MD - M. D. Anderson Cancer Center

Treatment of Naive Patients: What Are We Doing Today?

Gary R. Hudes, MD - Fox Chase Cancer Center

Treatment of Recurrent or Resistant Disease

Elisabeth I. Heath, MD - Karmanos Cancer Center

Managing Treatment Related Toxicities

Thomas Hutson, DO, PharmD - Texas Oncology

[Abstract #312](#): Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

Brian I. Rini, MD - Cleveland Clinic

Question and Answer Session

2:00 PM

Adjourn